Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health-care practitioners

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 691-699

  Grundmann, Oliver ^a   Yoon, Saunjoo L ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF NURSING   (United States)

Author keywords

Functional bowel disorders; Inflammatory bowel disease; Irritable bowel syndrome

Indexed keywords

ALOSETRON; BENZODIAZEPINE DERIVATIVE; CILANSETRON; CIMETROPIUM; CISAPRIDE; CODEINE; DARIFENACIN; DOMPERIDONE; GRANISETRON; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; METOCLOPRAMIDE; ONDANSETRON; OPIATE ANTAGONIST; OTILONIUM BROMIDE; PARGEVERINE; PINAVERIUM; PIRENZEPINE; PREGABALIN; RENZAPRIDE; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAMIFENACIN;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANXIETY DISORDER; BLURRED VISION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; ESCHERICHIA COLI; GASTROINTESTINAL MOTILITY; HEALTH CARE PERSONNEL; HUMAN; IRRITABLE COLON; ISCHEMIA; ISCHEMIC COLITIS; LIFESTYLE MODIFICATION; NAUSEA AND VOMITING; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK FACTOR; XEROSTOMIA;

EID: 77950142037     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06120.x     Document Type: Review

References (79)

1. Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol. Clin. North Am. 2005 34 : 173 187.
2. Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007 19 : 783 786.
3. WHO. International Statistical Classification of Diseases and Related Health Problems, 10th edn. Geneva, Switzerland : World Health Organization, 2007.
4. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978 2 (6138 653 654.
5. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 2002 97 (11 Suppl. S7 26.
6. Drossman DA, Douglas A, eds. Rome III: The Functional Gastrointestinal Disorder, 3rd edn. McClean, VA, USA : Degnon Associates, 2006.
7. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 2002 47 : 225 235.
8. Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. J. Epidemiol. 1995 142 : 76 83.
9. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005 34 : 205 220.
10. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005 34 : 247 255.
11. Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 2005 34 : 281 303.
12. Cash BD, Chey WD. Irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment. Pharmacol. Ther. 2004 19 : 1235 1245.
13. Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual. Life. Res. 2009 18 : 435 446.
14. Katsinelos P, Lazaraki G, Kountouras J et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Eur. J. Gastroenterol. Hepatol. 2009 21 : 183 189.
15. Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003 18 : 1412 1416.
16. Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004 20 : 339 345.
17. Bommelaer G, Dorval E, Denis P et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol. Clin. Biol. 2002 26 : 1118 1123.
18. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig. Dis. Sci. 1993 38 : 1581 1589.
19. Danivat D, Tankeyoon M, Sriratanaban A. Prevalence of irritable bowel syndrome in a non-Western population. BMJ (Clin. Res. Ed.) 1988 296 (6638 1710.
20. Kwan AC, Hu WH, Chan YK, Yeung YW, Lai TS, Yuen H. Prevalence of irritable bowel syndrome in Hong Kong. J. Gastroenterol. Hepatol. 2002 17 : 1180 1186.
21. Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J. Clin. Gastroenterol. 2009 43 : 541 550.
22. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002 122 : 1140 1156.
23. Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am. J. Gastroenterol. 1999 94 : 3530 3540.
24. Austin GL, Dalton CB, Hu Y et al. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2009 7 : 706 708.
25. Jones J, Boorman J, Cann P et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000 47 (Suppl. 2 ii1 19.
26. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009 104 (Suppl 1 S1 35.
27. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 2131.
28. Foell D, Wittkowski H, Ren Z et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 2008 216 : 183 192.
29. Olbe L. Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease. Scand. J. Gastroenterol. 2008 43 : 234 241.
30. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the 'no man's land' of gluten sensitivity. Am. J. Gastroenterol. 2009 104 : 1587 1594.
31. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J. Clin. Psychiatry 2001 62 (Suppl. 8 28 36 discussion 37.
32. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr. Opin. Gastroenterol. 2006 22 : 13 17.
33. O'Sullivan M, Clayton N, Breslin NP et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol. Motil. 2000 12 : 449 457.
34. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeabilityfollowing acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000 47 : 804 811.
35. Lee V, Guthrie E, Robinson A et al. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. J. Psychosom. Res. 2008 64 : 129 138.
36. Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur. J. Gastroenterol. Hepatol. 2004 16 : 1161 1166.
37. Rosen SD, Paulesu E, Nihoyannopoulos P et al. Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia. Ann. Intern. Med. 1996 124 : 939 949.
38. Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology 2002 122 : 290 298.
39. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J. Clin. Gastroenterol. 2005 39 (5 Suppl. 3 S184 193.
40. Brehmer A, Croner R, Dimmler A, Papadopoulos T, Schrodl F, Neuhuber W. Immunohistochemical characterization of putative primary afferent (sensory) myenteric neurons in human small intestine. Auton. Neurosci. 2004 112 : 49 59.
41. Nagakura Y, Kontoh A, Tokita K, Tomoi M, Shimomura K, Kadowaki M. Combined blockade of 5-HT3- and 5-HT4-serotonin receptors inhibits colonic functions in conscious rats and mice. J. Pharmacol. Exp. Ther. 1997 281 : 284 290.
42. Mazzia C, Hicks GA, Clerc N. Neuronal location of 5-hydroxytryptamine3 receptor-like immunoreactivity in the rat colon. Neuroscience 2003 116 : 1033 1041.
43. Taniyama K, Makimoto N, Furuichi A et al. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J. Gastroenterol. 2000 35 : 575 582.
44. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J. Neurosci. 1996 16 : 2352 2364.
45. Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004 126 : 1657 1664.
46. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009 9 : 15.
47. Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. J. Hum. Nutr. Diet. 2001 14 : 231 241.
48. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008 14 : 2650 2661.
49. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009 58 : 367 378.
50. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. 2000 108 : 65 72.
51. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am. J. Med. 1999 107 (5A 65S 73S.
52. Halpert A, Dalton CB, Diamant NE et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am. J. Gastroenterol. 2005 100 : 664 671.
53. Kall E, Lindstrom E, Martinez V. The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur. J. Pharmacol. 2007 570 : 203 211.
54. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 55 : 1095 1103.
55. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J. Gastroenterol. 2009 15 : 1548 1553.
56. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol. 2002 35 (1 Suppl. S58 67.
57. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am. J. Health Syst. Pharm. 2007 64 : 1020.
58. Sweetser S, Busciglio IA, Camilleri M et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 2009 296 : G295 301.
59. Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 2008 135 : 7.
60. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008 337 : a2313.
61. Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev. Gastroenterol. Disord. 2007 7 (Suppl. 3 S1 2.
62. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980 79 : 1272 1275.
63. Goldberg PA, Kamm MA, Setti-Carraro P, Van Der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996 57 : 478 483.
64. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991 41 : 574 595.
65. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin. Ther. 2008 30 : 884 901.
66. Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther. Clin. Risk Manag. 2008 4 : 41 8.
67. Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn. J. Pharmacol. 2001 86 : 281 288.
68. Wallis RM. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci. 1995 56 : 861 868.
69. Bradesi S, Herman J, Mayer EA. Visceral analgesics: drugs with a great potential in functional disorders? Curr. Opin. Pharmacol. 2008 8 : 697 703.
70. Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2006 1 : CD004116.
71. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998 280 : 1585 1589.
72. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment. Pharmacol. Ther. 2004 19 : 271 279.
73. Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002 65 : 161 171.
74. Krueger D, Gruber L, Buhner S et al. The multi-herbal drug STW 5 (Iberogast(R)) has prosecretory action in the human intestine. Neurogastroenterol. Motil. 2009 21 : 1203 e110.
75. Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can. Fam. Physician 2009 55 : 143 148.
76. Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment. Pharmacol. Ther. 1988 2 : 101 118.
77. Micklefield G, Jung O, Greving I, May B. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers. Phytother. Res. 2003 17 : 135 140.
78. Lim B, Manheimer E, Lao L et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2006 4 : CD005111.
79. Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr. Opin. Pharmacol. 2007 7 : 598 604.